FAQs - Corporate

（updated on April 3, 2026)

Q.	Tell us about the inauguration of the Company.
A.	Acugen Neuropeutics Inc. was established in Seattle, Washington, in the United States, on April 25, 2002, under the laws of the State of Washington to develop methods of treatment for degenerative eye diseases and a pharmaceutical compound screening system. The company name was changed to Acucela Inc. in March 2003. In December 2016, the company completed a triangle merger to establish Acucela Inc.'s parent company, Kubota Pharmaceutical Holdings Co., Ltd., based in Tokyo, Japan.
Q.	Why did you change the name of your U.S. subsidiary to Kubota Vision Inc. on April 1, 2020?
A.	In order for the Kubota Pharmaceutical Group to promote research and development of pharmaceuticals and medical devices globally, we made the change with the aim of unifying our corporate brands, which were different both domestically and internationally and increasing our recognition.
Q.	Why did you transfer your R&D and its management base from the U.S. to Japan?
A.	As announced in our July 17, 2024 press release, the research and development operations and their management functions, which had been carried out through our U.S. subsidiary, Kubota Vision Inc., have been transferred to our headquarters in Japan. In recent years, the cost of maintaining operations in the U.S. has continued to rise due to inflation and foreign exchange fluctuations, significantly impacting our overall business. In light of these circumstances, we made the strategic decision to integrate our R&D and its management functions into our existing management structure in Japan. This move is designed to establish a more efficient operational system and streamline our business processes.
Q.	What is the stock code of Kubota Pharmaceutical Holdings?
A.	The Company's stock code is 4596.
Q.	On which stock exchange is Kubota Pharmaceutical Holdings listed?
A.	The Company's common stock is currently listed on the Growth Market subsequent to the Tokyo Stock Exchange (TSE) market segment restructuring on April 4th, 2022. It was listed on the Mother's market of TSE on December 6, 2016. Originally, the Company first went public and was listed as Acucela Inc. on the Mother's Market on February 13, 2014.
Q.	When will you announce financial results?
A.	The Company's business year is from January 1 to December 31. Annual financial results are released in mid-February each year. We also disclose quarterly financial results.
Q.	What is the date of the annual meeting of shareholders of the Company?
A.	Our annual meeting of shareholders is held in Tokyo, Japan, prior to the end of May each year. Shareholders are to be informed of the date and venue of the meeting as soon as they are determined.
Q.	Why did the Company terminate the registration of its common shares and its reporting obligation in the U.S.?
A.	The Company considered the administrative burden and costs associated with being a U.S. reporting company and believes that the costs of maintaining registration in two jurisdictions outweighed the benefits received by the Company and our shareholders. The Company will continue to comply with its Japanese disclosure obligations through filings with the applicable Japanese securities regulators and its common shares will continue to trade on the Tokyo Stock Exchange Mothers Market.